Patents Assigned to Katholieke Universiteit Leuven K.U.
-
Patent number: 9573966Abstract: The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, Formulas (I), (II), (III) and (IV) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of proliferative disorders and pathologic conditions such as, but not limited to, cancer such as leukemia.Type: GrantFiled: September 8, 2011Date of Patent: February 21, 2017Assignee: Katholieke Universiteit Leuven, K.U.Leuven R&DInventors: Jean Herman, Thierry Louat
-
Patent number: 9569828Abstract: A method and apparatus for the imaging of a labeled biological sample. The method comprises illuminating the labeled biological sample, generating members of a time series of images if the labeled biological sample, generating a plurality of difference images between later members of the time series of images of earlier members of the time series of images and combining the plurality of difference images to generate a final image of the labeled biological sample.Type: GrantFiled: October 26, 2012Date of Patent: February 14, 2017Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Inventors: Sebastian Munck, Wim Annaert, Patrik Verstreken
-
Patent number: 9518066Abstract: The present invention relates to a class of novel isothiazolo[4,3-b]pyridine derivatives and a method for their preparation, as well as to pharmaceutical compositions comprising one or more of said isothiazolo[4,3-b]pyridine derivatives and one or more pharmaceutically acceptable excipients. The present invention further relates to the use of said novel isothiazolo[4,3-b]pyridine derivatives as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, cell-proliferative and neurodegenerative diseases.Type: GrantFiled: July 4, 2014Date of Patent: December 13, 2016Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Piet Herdewijn, Steven De Jonghe, Sona Kovachova, Lei Chang, Michal Sala
-
Publication number: 20160324828Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.Type: ApplicationFiled: July 21, 2016Publication date: November 10, 2016Applicants: Katholieke Universiteit Leuven, K.U.Leuven R&D, reMYNDInventors: Gerard Griffioen, Tom Van Dooren, Veronica Rojas de la Parra, Arnaud Marchand, Sara Allasia, Amuri Kilonda, Patrick Chaltin
-
Publication number: 20160304888Abstract: The present disclosure relates to the identification of a QTL associated with high ethanol tolerance in Saccharomyces spp. More specifically, it relates to specific alleles of MKT1 and APJ1 possibly combined with a specific allele of SWS2 that are important in obtaining a high ethanol tolerance in Saccharomyces spp. It relates further to the use of such alleles in the construction of high ethanol tolerant strains, and the use of these alleles in screening for ethanol tolerance.Type: ApplicationFiled: July 1, 2016Publication date: October 20, 2016Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&DInventors: Johan Thevelein, Maria Remedios Foulquie-Moreno, Annelies Goovaerts, Steve Swinnen
-
Patent number: 9464067Abstract: Disclosed are indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.Type: GrantFiled: June 18, 2012Date of Patent: October 11, 2016Assignees: Katholieke Universiteit Leuven K.U. Leuven R & D, Korea Research Institute of Chemical TechnologyInventors: Young Sik Jung, Chong Kgo Lee, Hae Soo Kim, Hee Chun Jeong, Pil Ho Kim, Soo Bong Han, Jin Soo Shin, Johan Neyts, Hendrik Jan Thibaut
-
Patent number: 9434722Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.Type: GrantFiled: October 22, 2013Date of Patent: September 6, 2016Assignees: Katholieke Universiteit Leuven, K.U. Leuven R&D, reMYNDInventors: Gerard Griffioen, Tom Van Dooren, Veronica Rojas De La Parra, Arnaud Marchand, Sara Allasia, Amuri Kilonda, Patrick Chaltin
-
Patent number: 9422573Abstract: Described are genes and chimeric genes encoding anti-microbial peptides. These genes can be used to generate transgenic plants with an improved resistance to, for example, plant pathogenic fungi. Alternatively, the peptides encoded by these genes can be applied as agrochemical formulations to plants suffering from microbial diseases such as fungal diseases.Type: GrantFiled: May 9, 2012Date of Patent: August 23, 2016Assignees: VIB VZW, Universiteit Gent, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Frank Van Breusegem, Annelies Inze, Janick Mathys, Bruno Cammue
-
Publication number: 20160237166Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: ApplicationFiled: September 11, 2013Publication date: August 18, 2016Applicants: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
-
Patent number: 9408885Abstract: The present disclosure relates to the field of oncology, more particularly to the field of melanoma. Provided are methods of treating melanoma, particularly advanced cutaneous melanoma, with a combination of pharmaceutical agents comprising MDM4-specific antagonists (such as an inhibitor of the MDM4-p53 interaction or a molecule that decreases MDM4 protein stability) or MDM4-MDM2 dual inhibitors (i.e., molecules that disrupt the interactions between p53 and MDM2 and p53 and MDM4) and one or more chemotherapeutic agents such as for example alkylating agents (i.e., Dacarbazine (DITC) or melphalan), alkylating-like agents (i.e., cisplatin or carboplatin) or mitotic inhibitors (taxanes docetaxel or paclitaxel) and PI3K-AKT, B-RAF and MEK inhibitors. Further provided are pharmaceutical formulations of MDM4-specific antagonists (be it an inhibitor of the MDM4-p53 interaction or a molecule that decreases MDM4 protein stability) or MDM4-MDM2 dual inhibitors (i.e.Type: GrantFiled: November 29, 2012Date of Patent: August 9, 2016Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventor: Jean-Christophe Marine
-
Patent number: 9389219Abstract: The disclosure relates to the fields of protein aggregation diseases including cancer. More specifically, it concerns a screening method for identifying compounds that inhibit or disrupt co-aggregation of one or more member proteins of a disease-related protein aggregome, in particular, a tumor-associated protein aggregome. Further, disclosed are agents and compounds identified by the screening method that can be applied to prevent or to treat protein aggregation diseases, such as cancer.Type: GrantFiled: March 26, 2012Date of Patent: July 12, 2016Assignees: Vrije Universiteit Brussel, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Joost Schymkowitz, Frederic Rousseau, Jie Xu, Frederik De Smet
-
Patent number: 9346749Abstract: Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.Type: GrantFiled: June 18, 2012Date of Patent: May 24, 2016Assignees: Korea Research Institute of Chemical Technology, Katholieke Universiteit Leuven K.U.Inventors: Young Sik Jung, Chong Kgo Lee, Ihl Young Choi, Hae Soo Kim, Pil Ho Kim, Soo Bong Han, Johan Neyts, Hendrik Jan Thibaut
-
Patent number: 9337273Abstract: A semiconductor device is provided comprising a bilayer graphene comprising a first and a second adjacent graphene layer, and a first electrically insulating layer contacting the first graphene layer, the first electrically insulating layer comprising an electrically insulating material, and a substance suitable for creating free charge carriers of a first type in the first graphene layer, the semiconductor device further comprising an electrically insulating region contacting the second graphene layer and suitable for creating free charge carriers of a second type, opposite to the first type, in the second graphene layer.Type: GrantFiled: March 29, 2013Date of Patent: May 10, 2016Assignees: IMEC, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Amirhasan Nourbakhsh, Mirco Cantoro, Cedric Huyghebaert, Mark Heyns, Stefan DeGendt
-
Patent number: 9301961Abstract: Compounds that bind to phosphatidylinositol-4-kinase III? (PI4KIII?) and inhibit the binding of PI4KIII? to its substrate and/or inhibit PI4KIII? activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating and/or preventing those pathological conditions, which comprises measuring the inhibition of PI4KIII? activity, is also disclosed.Type: GrantFiled: September 7, 2012Date of Patent: April 5, 2016Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Jean Herman, Thierry Louat, Qiuya Huang, Bart Vanderhoydonck, Mark Waer, Piet Herdewijn
-
Patent number: 9284271Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R1, R2, R4, R5, R6, E, n, Y1, Y2, Y3, Y4, Y5, B, R8, and m are as defined in the claims.Type: GrantFiled: December 13, 2011Date of Patent: March 15, 2016Assignees: Katholieke Universiteit Leuven, K.U. Leuven R&D, reMYNDInventors: Gerard Griffioen, Tom Van Dooren, VerĂ³nica Rojas De La Parra, Arnaud Marchand, Sara Alassia, Amuri Kilonda, Patrick Chaltin
-
Patent number: 9278958Abstract: The present invention relates to compounds having cytostatic activity against tumor cells. The compounds of the invention are of formula (I), or derivatives hereof, wherein R0, R1, R2, A, and X have defined meanings as described in claim 1.Type: GrantFiled: June 21, 2013Date of Patent: March 8, 2016Assignees: Katholieke Universiteit Leuven K.U. Leuven R&D, Universita Degli Studi Di FerraraInventors: Jan Balzarini, Wim Dehaen, Joice Thomas, Sandra Liekens, Romeo Romagnoli, Pier Giovanni Baraldi
-
Publication number: 20160030447Abstract: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HN2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections.Type: ApplicationFiled: October 16, 2015Publication date: February 4, 2016Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&DInventors: Steven De Jonghe, Ling-Jie Gao, Piet Herdewijn, Jean Herman, Miyeon Jang, Pieter Leyssen, Thierry Louat, Johan Neyts, Christophe Pannecouque, Bart Vanderhoydonck
-
Patent number: 9249420Abstract: The present invention relates to recombinant microorganisms comprising an isobutanol producing metabolic pathway and methods of using said recombinant microorganisms to produce isobutanol. In various aspects of the invention, the recombinant microorganisms may comprise one or more modifications resulting in the reduction in the expression and/or activity of an endogenous transporter protein. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.Type: GrantFiled: May 31, 2011Date of Patent: February 2, 2016Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Catherine Asleson Dundon, Christopher Smith, Piruz Nahreini, Johan Thevelein, Sofie Saerens
-
Patent number: 9249202Abstract: The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognized by a CD4+ T cell, more specifically, of an allergen or autoantigen, coupled, optionally, through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides may be used for the prevention or treatment of immune disorders, more specifically, of allergic disorders or autoimmune diseases. The present invention thus provides methods of treatment or preventing immune disorders by using such peptides.Type: GrantFiled: August 13, 2007Date of Patent: February 2, 2016Assignees: Life Sciences Research Partners VZW, Katholieke Universiteit Leuven, K.U.Leuven R&DInventor: Jean-Marie Saint-Remy
-
Patent number: 9227984Abstract: A series of monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.Type: GrantFiled: August 15, 2012Date of Patent: January 5, 2016Assignees: UCB Pharma S.A., Katholieke Universiteit Leuven, K.U.Leuven R&DInventors: Daniel Christopher Brookings, Daniel James Ford, Anant Ramrao Ghawalkar, Jean Herman, Qiuya Huang, Claire Louise Kulisa, Thierry Louat, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck